Venclexta is owned by Abbvie.

Venclexta contains Venetoclax.

Venclexta has a total of 10 drug patents out of which 0 drug patents have expired.

Venclexta was authorised for market use on 11 April, 2016.

Venclexta is available in tablet;oral dosage forms.

Venclexta can be used as treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up including a 100 mg per day dose, treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up that includes a dose of 50 mg per day for 1 week followed by 100 mg per day for 1 week, treatment of adults with relapsed, refractory or previously untreated chronic lymphocytic leukemia including a dose ramp-up and in combination with obinutuzumab in multiple 28-day dosing cycles followed by administration in absence of obinutuzumab, treatment of aml by orally administering venetoclax with azacitidine or decitabine or low-dose cytarabine to adults 75 years or older or having certain comorbidities per a dose ramp-up including an initial 100 mg or a final 400 mg per day dose, treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), with or without 17p deletion, who have received at least one prior therapy, treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic leukemia (sll) in combination with a ga101 antibody such as obinutuzumab for one or more dosing periods, wherein the cll or sll is a cd20-expressing cancer.

Drug patent challenges can be filed against Venclexta from 11 April, 2020.

The generics of Venclexta are possible to be released after 06 September, 2033.